Valneva SE, a specialty vaccine company, and Dynavax Technologies Corp., a biopharmaceutical company developing novel vaccines, have entered a commercial partnership for the supply of Dynavax’s CpG 1018 adjuvant for use in Valneva’s SARS-CoV-2 vaccine candidate, VLA2001.
Valneva separately has an agreement with the UK government to provide up to 190 million doses of VLA20011 over a five year period. Dynavax will supply CpG 1018 to produce up to 100 million doses of vaccine in 2021. Valneva has the option to purchase up to an additional 90 million doses through 2025.
Valneva expects VLA2001 to enter clinical studies by the end of 2020 and to potentially reach regulatory approval in 2H21. This commercial supply partnership follows the companies’ initial collaboration entered in April 2020 to advance COVID-19 vaccine development.